Researchers at the University of Arizona College of Medicine – Tucson have started to conduct a study to investigate the biological mechanisms that cause cataracts in the aim of developing new, nonsurgical treatments.
LensGen, Inc., a privately held ophthalmic medical device company, announced that the FDA has granted an Investigational Device Exemption (IDE) to begin a pivotal trial of its Juvene intraocular lens for cataract patients.
LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441 for its OcuRing Drug Delivery Platform.
A revolutionary new treatment for cataracts has shown extremely positive results in laboratory tests, giving hope that the condition, which currently can only be cured with surgery, could soon be treated with drugs.
Cataracts affect most older adults at risk for dementia, and new research shows that cataract surgery is linked to a lower risk of dementia.
AcuFocus announced that it has received an Approvable Letter from the FDA for its IC-8 small aperture IOL, which is designed for cataract patients.
LENSAR announced that the U.S. Food and Drug Administration (FDA) has accepted its 510(k) submission for its next-generation ALLY Adaptive Cataract Treatment System for substantive review.
Lensar announced FDA 510(k) clearance for its ALLY Adaptive Cataract Treatment System. ALLY is the first FDA-cleared platform to enable cataract surgeons to complete femtosecond-laser-assisted cataract surgery procedure in a single, sterile environment.
Bilateral implantation of the Tecnis Synergy IOL showed “very good” performence at all distances at 3 months of follow-up.
Rayner announced its direct entry into the French cataract and refractive market. Based out of Lille in the Hauts-de-France region, Rayner has a growing team of ophthalmic specialist area managers focused on delivering service and support.